Solid Stone Co (513699)
Asset PlayScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹33.31 |
| Market Cap | ₹18.21 Cr |
| P/E Ratio | 36.12 |
| ROCE | 7.68% |
| ROE | 2% |
| Dividend Yield | 0% |
| Profit Growth | -85.71% |
| Debt/Equity | — |
| Sales Growth | -44.84% |
| 52-Week Range | ₹21.66 — ₹39.95 |
| Sector | Other Construction Materials |
| Book Value | ₹43.31 |
Strengths
- Trading at a 23% discount to book value (P/B 0.77) with book value at ₹43.31 vs price ₹33.31.
- ROCE of 7.68% suggests the underlying assets still generate some operating return.
- Small market cap of ₹18 Cr leaves room for potential restructuring or asset realisation.
- Stock is above its 52-week low of ₹21.66, indicating a degree of market support.
Concerns
- Sales declined 44.84% and profit fell 85.71%, showing severe business shrinkage.
- Piotroski F-score of 3/9 signals weak financial health and possible red flags.
- No dividend and latest quarter net profit of ₹0 Cr means shareholders receive no current return.
- P/E of 36.12 is misleading with near-zero earnings, making the stock expensive on an earnings basis.
AI Analysis
Looking at Solid Stone Co, I see a classic cigar butt – a small ₹18 Cr company trading at ₹33.31 against a book value of ₹43.31. That's a 23% discount, which would usually interest a value investor like me. But I have to ask: what is the quality of that book value? The business is shrinking. Sales are down 44.84%, and profits have fallen 85.71%. The latest quarter shows sales of just ₹5 Cr and net profit of zero. Return on equity is only 2%, so the assets are barely earning anything. ROCE of 7.68% is better but still unimpressive for an industrial operation. The Piotroski F-score of 3 out of 9 is a serious warning sign; it tells me the company's financial position is deteriorating. There's no dividend to reward me while I wait. At a P/E of 36.12, the market is pricing in a recovery that I don't see in the numbers. As Graham would say, price is what you pay, value is what you get. Here, the balance sheet offers some support, but the earning power is weak and the moat is non-existent. This is a potential asset play, not a compounder. If the assets are truly worth book and management can stop the bleeding, the downside may be limited. But with sales falling so sharply, I want a bigger margin of safety. I'd only buy at a deeper discount to book, or when I see evidence of stabilisation. For now, it's a watchlist candidate, not a conviction buy.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer